Apex Ventures

Apex Ventures is a Munich-based early-stage venture capital firm specializing in deep technology and medical technology companies with defensible intellectual property. Founded by a team of entrepreneurs and operators, the firm has built a reputation for being a long-term strategic partner to founders building category-defining companies in AI, quantum technology, and life sciences.

Operating from offices in Munich and Seehausen, Apex Ventures manages approximately EUR 80 million in partnership with Amadeus Capital Partners through the Amadeus APEX Technology Fund. This vehicle allows the firm to make meaningful early-stage investments across the DACH region, Central and Eastern Europe, and the Nordics, with initial checks typically ranging from EUR 500,000 to EUR 1.5 million.

What distinguishes Apex Ventures from traditional financial investors is their hands-on, founder-first approach. The team, led by General Partners Andreas Riegler, Wolfgang Neubert, and Stefan Haubner, has direct experience building companies, which informs how they support portfolio founders through talent acquisition, business development, and subsequent fundraising rounds.

The firm is particularly active in the medical imaging AI space, having backed notable companies like contextflow, a spin-out from the Medical University of Vienna that automates analysis of medical imaging data. This sector expertise reflects the firm's broader thesis around leveraging artificial intelligence to transform healthcare delivery and diagnostic accuracy.

Understanding Apex Ventures's specific investment thesis and portfolio composition is essential for founders seeking capital. The firm is selective but engaged, and founders who can articulate a clear technical moat andScalable business model tend to resonate with the investment committee.

Apex Ventures invests at the intersection of scientific breakthrough and commercial viability. The firm's investment thesis centers on supporting visionary founders who are building companies grounded in unique and protectable technology, rather than purely商业模式-driven startups.

The Amadeus APEX Technology Fund, a partnership between Amadeus Capital Partners and Apex Ventures launched in early 2023, represents approximately EUR 80 million in deployable capital specifically targeting European deep tech at the earliest stages. Amadeus brings over $1.3 billion in raised capital and a strong track record in enterprise software and life sciences, complementing Apex's operational focus.

Within deep tech, Apex Ventures shows particular affinity for companies working in AI and machine learning applications, quantum computing and sensing technologies, biotechnology and medical devices, and advanced materials or photonics. The common thread is technical differentiation that creates meaningful barriers to entry.

The firm evaluates opportunities based on scientific differentiation, the quality and completeness of the research team, the strength of any intellectual property position, and the potential for transformative impact in its target markets. Apex Ventures is not looking for incremental improvements to existing products; the firm seeks companies that could fundamentally reshape their industries.

Beyond capital, Apex Ventures provides portfolio companies with access to a network of scientific advisors and industry partners who understand the unique challenges of building deep technology businesses. This includes assistance with hiring top technical talent, navigating regulatory pathways in healthcare and medical technology, and identifying commercial partnerships that accelerate time to market.

Apex Ventures has maintained an active investment pace through 2025 and into early 2026, with several portfolio companies completing significant funding rounds. The firm participated in recent financing activities for contextflow and ImageBiopsy Lab, both companies operating in the medical imaging AI space where Apex has built deep sector expertise.

The Amadeus APEX Technology Fund partnership has given Apex Ventures greater firepower to lead or co-lead rounds in a market where many deep tech种子阶段 companies struggle to find institutional backing. The firm has been particularly active in the DACH region, where a concentration of world-class technical universities produces a steady stream of spin-out opportunities.

Mobius Labs, a Berlin-based company developing lightweight AI algorithms for edge devices, represents another notable Apex portfolio company. The company recently achieved significant commercial milestones, reflecting the firm's ability to identify and support companies building genuinely differentiated technology.

Apex Ventures has also continued to support its existing portfolio through follow-on rounds, demonstrating a commitment to long-term partnerships with founders rather than a transactional approach to venture investing. The firm's principals are accessible and engaged, working closely with portfolio company leadership on strategic decisions.

The broader market environment has influenced how Apex Ventures approaches deployment. The firm has become more rigorous in its due diligence processes, placing additional emphasis on path to commercial traction and unit economics even at the earliest stages. However, the firm remains committed to its core thesis and will invest in exceptional founders regardless of broader market sentiment.

Apex Ventures's portfolio reflects its thesis around deep tech and intellectual property-driven companies. The firm's holdings span multiple technology sectors, with particular concentration in artificial intelligence applications for healthcare and industrial use cases.

contextflow is perhaps the most well-known Apex portfolio company. Founded as a spin-out from the Medical University of Vienna, contextflow has developed automated processes for analyzing medical imaging data, leveraging deep learning to improve diagnostic accuracy and reduce radiologist workload. The company represents Apex's thesis around applying AI to large, underserved healthcare problems with clear regulatory pathways.

ImageBiopsy Lab, another medical imaging AI company in the Apex portfolio, focuses on AI-driven analysis of tissue samples for pathology applications. Both companies benefit from the firm's deep network in the European medical technology ecosystem and the operational experience of the Apex team.

Mobius Labs, based in Berlin, has taken a different approach, developing highly performant and lightweight AI algorithms packaged as software development kits that enable edge devices such as mobile phones and IoT hardware to run sophisticated machine learning models without cloud connectivity. This architecture addresses growing concerns around data privacy and latency while opening new markets for AI at the edge.

Other notable holdings include kiutra (magnetic cooling technology for quantum computing applications), CardiaTec (AI-powered cardiovascular risk assessment), Refined Laser Systems (precision laser instrumentation), and Zetta Genomics (genomic data analysis). The diversity of the portfolio reflects Apex's openness to exceptional technical teams across deep tech sub-sectors.

Portfolio companies benefit from Apex's active engagement model. The firm does not take a passive approach post-investment; instead, principals work closely with founders on product development, commercial strategy, and subsequent fundraising. This hands-on philosophy extends to leveraging the broader network of scientific advisors and industry partners that Apex has cultivated over its history.

Apex Ventures evaluates potential investments through a rigorous process that prioritizes technical differentiation and founder quality above market size or growth metrics. The firm is explicitly looking for companies that could not have been built a decade ago, where advances in underlying technology create the conditions for transformative businesses.

The founding team is the single most important factor in Apex's investment decision. The firm looks for entrepreneurs with deep domain expertise, ideally rooted in academic research or prior industry experience, who can articulate a clear vision for how their technology solves a meaningful problem. Technical co-founders with publication records or demonstrated ability to execute on hard technical problems receive significant weight.

Intellectual property position is critical for Apex Ventures. Companies with existing patents, proprietary datasets, or unique technical approaches that create meaningful barriers to competition are preferred over those relying primarily on speed or execution to maintain advantage. The firm has legal and technical advisors who evaluate IP strength as part of the due diligence process.

Market opportunity matters, but not in the way it might for a consumer-focused VC. Apex Ventures seeks large, real problems where existing solutions are inadequate, but the firm is more interested in whether the technical solution can achieve commercial traction than in abstract market size projections. A company addressing a real pain point in healthcare or industrial automation with a differentiated solution will resonate more than one chasing an artificially inflated TAM.

Product-market fit evidence is valued, particularly for companies that have begun commercial engagement. Apex Ventures understands that deep tech companies often have long development cycles, so early traction might be defined as pilot agreements, LOIs from potential customers, or demonstrated performance metrics that validate the technical approach.

Cultural alignment and founder coachability are evaluated as part of the qualitative assessment. The firm looks for founders who are open to input, willing to adapt their approach based on market feedback, and committed to building lasting companies rather than chasing a quick exit.

Reaching Apex Ventures requires understanding how the firm sources deal flow. The majority of Apex's best investments come through warm introductions from its network of founders, co-investors, and industry partners. Building genuine relationships with the venture community in the DACH region and broader European tech ecosystem is the most effective path to getting in front of the Apex team.

Portfolio company referrals carry significant weight. If you have connections to founders in the Apex portfolio or have been introduced by investors who have worked with the firm previously, that context dramatically increases the likelihood of a response. Apex tracks referral sources and gives appropriate credit to advocates in its network.

Cold outreach through the firm's website (info@apexventures.de) is possible but requires a highly targeted approach. Your pitch must clearly articulate why your company aligns with Apex's specific thesis around protectable technology in deep tech and medical technology sectors. Generic pitch decks or companies clearly outside the firm's focus areas will not receive responses.

Conference participation is another avenue for connection. Apex Ventures partners appear regularly at European deep tech and venture events, including programs through Hello Tomorrow and other industry gatherings. Building visibility in the European deep tech community before pitching can pay dividends when you are ready to raise.

When you do secure a meeting, be prepared for a technical due diligence process. Apex's investment committee will include individuals with deep domain expertise who will ask detailed questions about your technology, its differentiation, and your intellectual property position. Be ready to defend your technical approach with data and evidence.

Follow-up discipline matters to Apex Ventures. After an initial meeting, expect a several-week process for the firm to complete its evaluation. Maintain communication with appropriate frequency, sharing material updates on your company's progress. Avoid being pushy or demanding immediate decisions; the firm evaluates companies on their own timeline.

While Apex Ventures is a deep tech investor focused on technical differentiation, financial preparedness remains an expectation in due diligence. The firm wants to see that founders understand the economics of their business, including unit economics, customer acquisition costs, and the path to profitability or the next equity round.

Early-stage deep tech companies often have limited commercial revenue, but Apex Ventures will still evaluate the quality of your financial planning. Have clear assumptions about how you will deploy the capital you raise, what milestones you expect to achieve, and how you will approach subsequent fundraising if needed.

Working with a fractional CFO can meaningfully improve your readiness for the Apex Ventures due diligence process. Professional financial guidance helps you build investor-grade projections, prepare detailed financial models that withstand scrutiny, and confidently discuss your business economics.

Our team has guided numerous companies through venture capital fundraising processes. We understand what deep tech investors like Apex Ventures look for in financial presentations and can help you prepare materials that accurately represent your business potential while highlighting your technical differentiation.

Financial projections should be grounded in evidence and defensible assumptions. Apex Ventures will challenge optimistic projections and expects founders to have considered multiple scenarios. Be prepared to explain the basis for your forecasts and demonstrate that you understand both the technical and commercial dimensions of your business.

Understanding your key performance indicators is essential when presenting to any sophisticated investor. Track the metrics that matter most to your business, whether that is patient or customer acquisition metrics for healthcare companies, technical performance benchmarks for AI companies, or burn rate and runway for capital-intensive deep tech businesses.

Whether you are preparing to pitch Apex Ventures or any other sophisticated deep tech investor, professional financials can differentiate you from founders who have not done the work to understand their business economics. Our team helps you build the financial foundation that supports a successful fundraising process.

Exploring other venture capital firms? Our comprehensive collection of VC firm reviews covers hundreds of investors across all stages and sectors.

Each review provides detailed information about investment criteria, portfolio companies, and tips for securing funding. Whether you are looking for seed-stage investors or growth equity firms, you will find valuable insights in our VC firm guides.

Finding the right investor for your startup is crucial to your success. Take the time to research potential investors and understand their specific investment thesis before reaching out.

Our guides cover major venture capital firms as well as emerging managers that may be a better fit for your company's specific needs and stage of development.